Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Retained Earnings (2020 - 2025)

Maxcyte (MXCT) has disclosed Retained Earnings for 6 consecutive years, with -$251.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 22.12% to -$251.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$251.9 million, a 22.12% decrease, with the full-year FY2024 number at -$216.9 million, down 23.35% from a year prior.
  • Retained Earnings was -$251.9 million for Q3 2025 at Maxcyte, down from -$239.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$106.7 million in Q2 2021 to a low of -$251.9 million in Q3 2025.
  • A 5-year average of -$167.9 million and a median of -$164.9 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: dropped 18.63% in 2022, then decreased 28.15% in 2023.
  • Maxcyte's Retained Earnings stood at -$114.3 million in 2021, then dropped by 20.62% to -$137.9 million in 2022, then fell by 27.51% to -$175.8 million in 2023, then decreased by 23.35% to -$216.9 million in 2024, then fell by 16.16% to -$251.9 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Retained Earnings are -$251.9 million (Q3 2025), -$239.5 million (Q2 2025), and -$227.1 million (Q1 2025).